Direct Binding of Vx-809 to Human Cftr Nbd1

نویسندگان

  • Rhea P. Hudson
  • Jennifer E. Dawson
  • P. Andrew Chong
  • Zhengrong Yang
  • Linda Millen
  • Philip J. Thomas
  • Christie G. Brouillette
  • Julie D. Forman-Kay
چکیده

Molecular Structure and Function, Peter Gilgan Center for Research and Learning, Hospital for Sick Children (R.P.H, J.E.D., P.A.C., J.F.-K.) and Department of Biochemistry, University of Toronto (J.F.-K.), Toronto, ON, Canada; Center for Structural Biology (Z.Y., C.G.B.) and Department of Chemistry (C.G.B.), University of Alabama at Birmingham, Birmingham, AL, USA; Department of Physiology at UT Southwestern Medical Center at Dallas Forest Park, Dallas, TX, USA (L.M., P.J.T.). This article has not been copyedited and formatted. The final version may differ from this version. Molecular Pharmacology Fast Forward. Published on May 25, 2017 as DOI: 10.1124/mol.117.108373

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface.

Understanding the mechanism of action of modulator compounds for the cystic fibrosis transmembrane conductance regulator (CFTR) is key for the optimization of therapeutics as well as obtaining insights into the molecular mechanisms of CFTR function. We demonstrate the direct binding of VX-809 to the first nucleotide-binding domain (NBD1) of human CFTR. Disruption of the interaction between C-te...

متن کامل

VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1

Cystic fibrosis (CF) is a fatal genetic disorder associated with defective hydration of lung airways due to the loss of chloride transport through the CF transmembrane conductance regulator protein (CFTR). CFTR contains two membrane-spanning domains (MSDs), two nucleotide-binding domains (NBDs), and a regulatory domain, and its channel assembly requires multiple interdomain contacts. The most c...

متن کامل

Mechanism-based corrector combination restores ΔF508-CFTR folding and function.

The most common cystic fibrosis mutation, ΔF508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of ΔF508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug develo...

متن کامل

Corrector VX-809 stabilizes the first transmembrane domain of CFTR.

Processing mutations that inhibit folding and trafficking of CFTR are the main cause of cystic fibrosis (CF). A potential CF therapy would be to repair CFTR processing mutants. It has been demonstrated that processing mutants of P-glycoprotein (P-gp), CFTR's sister protein, can be efficiently repaired by a drug-rescue mechanism. Many arginine suppressors that mimic drug-rescue have been identif...

متن کامل

Synergy-Based Small-Molecule Screen Using a Human Lung Epithelial Cell Line Yields DF508-CFTR Correctors That Augment VX-809 Maximal Efficacy

The most prevalent cystic fibrosis transmembrane conductance regulator (CFTR) mutation causing cystic fibrosis, DF508, impairs folding of nucleotide binding domain (NBD) 1 and stability of the interface between NBD1 and the membranespanning domains. The interfacial stability defect can be partially corrected by the investigational drug VX-809 (3-[6-[[[1-(2,2difluoro-1,3-benzodioxol-5-yl)cyclopr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2017